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lacking.We have developed an in-vivomodel to assess specificity and
efficacy of CMV-CTL and establish TC doses required for treat-
ment using colon carcinoma cells transduced with CMVpp65 as
a surrogate system. HLA A02011 human colon carcinoma cells
transduced with CMVpp65 and GFP-firefly luciferase (CoCa-
pp65) were injected subcutaneously (s.c.) into NOD/Scid-IL2Rgc-
KO/J mice (NSG) at doses ranging from 104–106 (4 mice /group)
and tumor growth followed for 4 weeks using bio-luminescent imag-
ing and tumor measurements. Consistent engraftment was observed
with 3  105 cells. Groups of NSG mice were then injected s.c with
CoCa-pp65 (3  105) mixed with HLA A0201-restricted CMV-
CTL (A2-CMV-CTLs) at E:T ratios of 50:1, 10:1, 2:1 and 0.4:1.
To ascertain antigen specificity of A2-CMV-CTLs, groups of 4
NSG mice were subsequently co-injected s.c. with 3 tumor-TC
combinations (E:T 5 1:1) as follows: (i) A2-CMV- CTLs 1 3 
105 CoCa-pp65 (ii) A2-CMV- CTLs 1 A2 tumor without
CMVpp65 (iii) A2-Flu-CTLs 1 3  105 CoCa-pp65. Control ani-
mals were injected with the 2 tumors without TC. IL-2 (2000 U
i.p) was given 2  a week, growth followed by imaging x 4 weeks.
No growth of CoCa-pp65 was detected in any animal co-injected
with A2-CMV-CTL at any E:T ratio, with consistent tumor growth
over 4 weeks in controls. Current experiments are assessing E:T ra-
tios lower than 0.4:1. Tumor growth was observed in control groups
(ii) and (iii) with no detectable growth in (i) by imaging or examina-
tion of autopsied tissues. These studies demonstrate that CMV-
CTL can eradicate clonogenic tumor cells expressing an immuno-
genic viral antigen in-vivo at E:T ratios that are significantly lower
than those required in-vitro. This model also allows for comparison
of cytotoxic activity of TC directed against different immunogenic
epitopes and permits comparisons of virus-specific and tumor spe-
cific TC for their immunotherapeutic potential.374
OVERCOMING ANTIGENIC COMPETITION TO PRODUCE MULTISPECIFIC
CYTOTOXIC T LYMPHOCYTE LINES FOR ADOPTIVE TRANSFER
Leen, A.M., Christin, A., Gerdemann, U., Vera, J.F., Heslop, H.E.,
Brenner, M.K., Rooney, C.M. Center for Cell and Gene Therapy, Baylor
College of Medicine, The Methodist Hosptial, Texas Children’s Hospital,
Houston, TX
HSCT recipients are susceptible to lethal opportunistic infec-
tions, which are often not amenable to conventional therapies. We
have shown that adoptive transfer of just 2  105/kg in vitro ex-
pandedmultivirus-specific cytotoxic T lymphocyte lines (CTLs) tar-
geting EBV, CMV, and Adv can protect against these infections.
Within eachCTL line, however, Adv-specificT cells were aminority
of the total. Furthermore, epitope analysis showed a small number of
Adv epitopes recognized by the trivirus lines, potentially limiting
their antiviral potency. This low frequency and restricted epitope
recognition is likely due to antigen/epitope competition and we
have now devised a means to overcome the problem so that we can
extend the approach to produce CTLs targeting additional viral
pathogens. We proposed that antigenic competition could be over-
come by promoting the survival of T cells with subdominant speci-
ficities using IL-4 and IL-7. Co-culture in the presence of these
cytokines individually or in combination increased total T cell ex-
pansion by 2–6 fold. Further, within 9 days of culture, cytokine-sup-
plemented CTLs had enhanced reactivity (measured by IFNg
ELIspot) against multiple immunodominant and subdominant viral
epitopes from EBV, CMV, and Adv. For example, Adv specificity in
the trivirus CTL detected responses against 5.25 hexon-peptide
pools (range 4–12) vs 1.5 pools (range 0–4) in ‘‘standard’’ CTL
from the same donors (n 5 6). Reactivity to CMV-pp65 was also
broader (10 pools (range 8–15) vs 4 (range 4–5). Anti-viral specific-
ities were sustained over multiple rounds of in vitro stimulation,
and the CTLs were cytolytic in chromium release and co-culture as-
says. In contrast, standard CTLs were only cytolytic against immu-
nodominant antigens. To date, addition of these cytokines has
allowed us to produce single cell lines containing effector cells spe-
cific for multiple epitopes in EBV, CMV, Adv, and BK antigens.
This technology will allow us to produce a single T cell product
which can safely protect against a wide range of pathogens simulta-
neously.375
EXPANSION OF REGULATORY T CELLS WITH ULTRA LOW-DOSE IL-2
AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION
Kennedy-Nasser, A.A., Ku, S., Chaiyarat, W., Foster, A., Savoldo, B.,
Yvon, E., Leung, K.S., Carrum, G., Kamble, R.T., Heslop, H.E.,
Brenner, M.K., Krance, R.A., Bollard, C.M. Baylor College of Medicine,
Texas Children’s Hospital and the Methodist Hospital, Houston, TX
CD41 CD251 FoxP31 regulatory T cells (Tregs) are of increas-
ing interest in hematopoietic stem cell transplantation (HSCT)
since they may help prevent graft-versus-host disease (GvHD). Mu-
rine models demonstrate that infusion of donor-derived Tregs to
HSCT recipient mice can prevent GvHD by suppressing alloreac-
tive T cell responses, while human recipients of allografts with low
Treg numbers have increased rates of GvHD. We and others have
previously given low-dose IL-2 to HSCT recipients in an attempt
to enhance antitumor immunity. Although no definitive antitumor
effects were observed, the patients were noted to have low rates of
GvHD. Retrospectively, it has been demonstrated that patients who
received IL-2 therapy had higher levels of FoxP31 T cells (i.e.,
Tregs) than controls, suggesting that IL-2 preferentially expands
Tregs in vivo, thereby preventing GvHD. We have therefore initi-
ated a phase I/II clinical trial to evaluate the efficacy and toxicity of
low-dose IL-2 injections following allogeneic HSCT. The intent is
to promote Treg expansion in vivo and prevent acute GvHD. Thus
far, 5 patients who received a HSCT for hematologic malignancies
have been treated with ultra low-dose IL-2 (100,000 to 200,000
units/m2 subcutaneously three times weekly) beginning day 17 to
day 128 after HSCT, for 6 to 12 weeks. Median age at time of
transplant was 21 years (range, 9 to 56 years). Two patients received
matched sibling donor transplants and three received alternative
donor transplants with Campath 1-H for in vivo T-cell depletion.
Flow cytometric analysis of blood from all patients demonstrated
a rise in the percentage of CD41 CD251 FoxP31 Tregs by 6 weeks
following initiation of IL-2 therapy with mean of 4.7% (range, 0 to
9.8%) pre IL-2 to a mean of 17.7% (range, 7.8 to 31.1%) after IL-2
treatment. Functional analyses of these CD41 CD25bright cells
showed suppression of thymidine uptake in mixed lymphocyte cul-
tures. No grade 3 or 4 toxicities occurred while on IL-2. No patient
developed . grade I acute GvHD. One patient who did not com-
plete the full 12 weeks of IL-2 therapy developed extensive, chronic
GvHD two months after stopping IL-2. In conclusion, low-dose
IL-2 is relatively well tolerated and may expand a CD41 CD251
FoxP31 Treg population in vivo. Their effects on GvHD and re-
lapse remain to be determined.376
RECOVERY OF IMMUNE CELL SUBSETS POSTTRANSPLANT IS ASSOCI-
ATED WITH INFECTION RISK BUT NOT SURVIVAL, RELAPSE OR NON-
RELAPSE MORTALITY
Geddes, M.1, Barry, S.2, Michael, B.2, Storek, J.1 1University of Calgary,
Calgary, AB, Canada; 2Fred Hutchinson Cancer Center, Seattle, WA
Background: Late recovery of total lymphocyte, CD4 T cell,
CD8 T cell, B cell or monocyte counts post transplant has been as-
sociated with poor transplant outcomes, including infections, in
some but not all studies involving relatively small numbers of pa-
tients. We set out to determine whether transplant outcomes could
be predicted from immune cell subset counts in a relatively large
group of patients (n 5 98) with long follow up (4 1⁄2 years).
Methods: In recipients of matched sibling myeloablative trans-
plant performed in 1996–2000 we prospectively measured the fol-
lowing immune subsets at day 30, 80, 180 and 365: total B cells,
IgD1 (naive) B cells, IgD- (memory) B cells, CD41 T cells,
CD81 T cells, CD41CD81 cells, CD4-CD8- T cells, CD281
(costimulation-competent) or CD28- CD4 or CD8 T cells, naı¨ve
(CD45RAhigh) or memory (CD45RAlow/neg) CD4 T cells, naı¨ve
(CD11alow) or memory (CD11ahigh) CD8 T cells, NK cells and
monocytes. Outcomes determined from a retrospective chart review
included total, definite (microbiologically documented), bacterial,
fungal, viral, HSV, VZV, and CMV infections in the intervals of
days 30–80, 81–180, 181–365, and .365 post transplant, as well as
overall survival, relapse, non-relapse mortality and fatal infection.
Poster Session-II 135Follow up for infections was censored at time of relapse or death.
Hazard ratios (HR) of outcome of patients with above vs below me-
dian immune subset count at the beginning of each interval were de-
termined. The HR was adjusted for disease stage, stem cell source,
immunosuppressive therapy for GVHD, and use of antimicrobial
prophylaxis. Due to multiple comparisons, HR was considered sig-
nificant only if p\0.01.
Results:No association was found between an immune cell subset
count and fatal infection, non-relapse mortality, survival, or relapse.
Regarding infections, the only significant association between a day
30 subset count and day 30–80 infections was betweenCD4-CD8-T
cells and viral infections. For the subsequent time intervals, conspic-
uous associations are shown in Table 1.
Immune cell subset above the median and hazard ratio of
definite and bacterial infections
Bacterial Definite Bacterial Definite Bacterial DefiniteSubsetinfection
d81-180
HR(p)
infection
d81-180
HR(p)infection
d181-365
HR(p)
d
infection
181-365
HR(p)
infection
d.365
HR(p)infection
d.365
HR(p)Total B
cells (0.18
p50.002)NS 0.07
(p50.0005)NS NS NSNaive B
cells (0.24
p50.006)NS 0.07
(p50.0005)NS NS NSMemory
B cellsNS NS NS NS NS 0.4 (0.002)NK cells NS 0.45
(p50.01)0
(p50.003) (0.2
p50.001)NS NSCD4
memory/
effector
cellsNS NS NS 0.25
(p50.002)NS NSNS 5 not significant.
Conclusion: In contrast to previous studies, no association was
found between an immune cell subset count and fatal infection,
non-relapse mortality, survival, or relapse. Associations between
some immune cell subset counts and infections exist and should be
further studied.377
GENERATION OF VIRUS-SPECIFIC CYTOTOXIC T LYMPHOCYTES (CTLS)
RESISTANT TO THE IMMUNOSUPPRESSIVE DRUG TACROLIMUS (FK506)
De Angelis, B.1,2, Dotti, G.1, Quintarelli, C.1,2, Huye, L.E.1, Zhang, L.1,
Zhang, M.1, Heslop, H.E.1, Brenner, M.K.1, Rooney, C.M.1, Savoldo, B.1
1Baylor College of Medicine, Houston, TX; 2University of Naples Federico
II, Naples, Italy
Viral infections (CMV, EBV and Adenovirus) can be fatal compli-
cations post allogeneic hematopoietic stem cell and solid organ
transplantation. Administration of virus-specific CTLs, targeting in-
dividual- or multiple-viral antigens is effective in these patients.
However, in those whose immunosuppressive treatment needs to
be maintained to prevent GvHD or organ rejection, expansion and
persistence of adoptively transferred virus-specific CTLs are im-
paired. FK506 is frequently used as immunosuppressive drug. Its ef-
fects depend on binding to FKBP12 proteins. SinceT cells generated
from FKBP12 knockout mice are resistant to the inhibitory effects of
FK506, we knocked down FKBP12 using a small interfering RNA
(siRNA) to generate virus- specific CTLs resistant to FK506. As
a model we used EBV1 tumor and EBV-CTLs. We identified one
siRNA sequence (siRNA4), that knocked down .90% of FKBP12
expression in T cell lines and virus-CTLs. We then generated 2 ret-
roviral vectors encoding for siRNA4/eGFP and irrelevant siRNA/
eGFP and used them to transduce CTLs generated from 7 EBV-
seropositive donors. Transduction efficiency was 46 6 22% for
siRNA4 and 556 27% for irrel.-siRNA. We measured the prolifer-
ation of transduced CTLs in the presence of FK506, in short and
long term cultures. We found that in the presence of FK506, prolif-
eration of control CTLs was significantly inhibited (by 746 2%) as
compared to siRNA41 CTLs (41 6 4%). In long term cultures,modified CTLs were stimulated weekly with EBV1 cells, with or
without FK506 (5ng/ml) and low dose IL-2 (20U/mL). The propor-
tion of siRNA41CTLs increased over time not only as a percentage
of GFP1 cells (from 466 22% to 896 5% after 5 stimulations) but
also numerically (34median fold expansion, range 5–60). In contrast,
control CTLs did not show any selection in culture, as the percent-
age of GFP1 cells remained unchanged (from 56 6 27% to 57 6
23%) and CTLs ceased to proliferate (2 median fold expansion,
range 0–5). Finally, we found that siRNA41 CTLs retained their
MHC-restricted cytotoxicity against EBV1 cells (66 6 22% lysis
at an E:T ratio of 20:1). Modified CTLs also maintained their pro-
duction of IFN-g in response to EBV-peptides, as assessed by ELI-
spot assays. In conclusion, we have developed a strategy that
produces virus-specific CTLs resistant to FK506. This strategy
may be beneficial to improve virus immune reconstitution in patients
post transplant, despite ongoing immunosuppresion.378
ASSOCIATION BETWEEN HLA-E POLYMORPHISM AND SEVERE FUNGAL
INFECTIONS AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION
Testa, G.V.1, Tamouza, R.2, Busson, M.2, Fortier, C.2, Marques, S.B.1,
Charron, D.2, Vigorito, A.C.1 1UNICAMP, Campinas, Sao Paulo, Bra-
zil; 2Hopital Saint Louis, Paris, France
HLA-E is a non classical HLA class I molecule that interacts with
NK cell CD94/NKG2 family receptors as a major ligand playing
a dual role in NK cell modulation and T cell activation, either inhib-
iting or triggering the citotoxicity by these cells. These roles indicate
the involvement of HLA-E antigen in host-immune response against
pathogens. The aim of this studywas to evaluate whether theHLA-E
alleles have functional impact on the incidence of bacterial, viral and
fungal infections in patients who have undergone an HLA identical
sibling myeloablative hematopoietic stem cell transplantation
(HSCT). One hundred and seven patients and their respective do-
nors were included in this study. HSCT was performed from 1999
to 2006, with a minimum of 6 months follow up. The distinction be-
tween HLA-E*0101 and HLA-E*0103 alleles was done either by
polymerase chain reaction – restriction fragment length polymor-
phism (PCR-RFLP) and polymerase chain reaction – sequence spe-
cific primer (PCR-SSP). The predictive effect of HLA-E genotype
(HLA-E* 0101/ E*0101, E* 0101/E* 0103 and E*0103/ E*0103)
was assessed as variables.Univariate analysis using death as a compet-
ing risk were done to evaluate the association between HLA-E poly-
morphism with first infections episodes. HLA-E genotype showed
no association with severe bacterial infection or viral infections.
However, in first severe fungal infection episode HLA-E* 0101/
E*0101 genotype was found to have a protective effect (P 5 0.01),
since none of the patients who had severe fungal infections had
this haplotype. In conclusion, it is possible that HLA-E genotype
polymorphism fulfills a related function to fungal infection after
HSCT, although these are preliminary data and need further
confirmation.379
A ROLE FOR IRAK-M IN PGE2-INDUCED IMMUNOSUPPRESSION POST-
BONE MARROW TRANSPLANT
Hubbard, L.L.N.1, Ballinger, M.N.2, Standiford, T.J.2, Moore, B.B.2
1University of Michigan, Ann Arbor, MI; 2University of Michigan,
Ann Arbor, MI
Rationale: Following bone marrow (BM) transplantation (BMT),
patients are susceptible to lung infections. In a mouse model of syn-
geneic BMT, we have shown BMT alveolar macrophages (AMs) and
alveolar epithelial cells (AECs) overproduce prostaglandin E2
(PGE2) relative to non-transplant controls. Overproduction of
PGE2 significantly impairs neutrophil killing and inhibits both
phagocytosis and killing in AMs. These defects are also associated
with diminished TNF-alpha production. However, a mechanism
by which PGE2 overproduction suppresses lung innate immune
cell function post-BMT is unknown. As interleukin-1 receptor asso-
ciated kinase (IRAK)-M is a known inhibitor of MyD88-dependent-
